Shares of Shield Therapeutics plc (LON:STX – Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 3.06 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.10 ($0.04), with a volume of 893,979 shares trading hands.
Shield Therapeutics Stock Performance
The company has a market cap of £29.61 million, a price-to-earnings ratio of -0.77 and a beta of 1.42. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The stock’s fifty day simple moving average is GBX 3.07 and its 200 day simple moving average is GBX 3.39.
Insider Buying and Selling at Shield Therapeutics
In other news, insider Anders Lundstrom purchased 575,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($29,750.36). 62.16% of the stock is owned by insiders.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Stories
- Five stocks we like better than Shield Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Stock Sentiment Analysis: How it Works
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Comparing and Trading High PE Ratio Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.